Your browser is no longer supported. Please, upgrade your browser.
Citius Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.47 Insider Own9.14% Shs Outstand134.70M Perf Week-5.91%
Market Cap301.72M Forward P/E7.19 EPS next Y0.31 Insider Trans0.00% Shs Float68.11M Perf Month22.53%
Income-21.40M PEG- EPS next Q-0.07 Inst Own6.70% Short Float19.20% Perf Quarter67.67%
Sales- P/S- EPS this Y42.00% Inst Trans2.15% Short Ratio0.83 Perf Half Y124.01%
Book/sh0.45 P/B4.96 EPS next Y191.20% ROA-59.40% Target Price- Perf Year135.98%
Cash/sh0.03 P/C70.17 EPS next 5Y- ROE-77.70% 52W Range0.77 - 2.90 Perf YTD118.63%
Dividend- P/FCF- EPS past 5Y20.00% ROI- 52W High-23.10% Beta1.61
Dividend %- Quick Ratio1.60 Sales past 5Y- Gross Margin- 52W Low189.61% ATR0.17
Employees10 Current Ratio1.60 Sales Q/Q- Oper. Margin- RSI (14)61.54 Volatility9.77% 8.97%
OptionableNo Debt/Eq0.02 EPS Q/Q1.00% Profit Margin- Rel Volume0.41 Prev Close2.17
ShortableYes LT Debt/Eq0.01 Earnings- Payout- Avg Volume15.74M Price2.23
Recom2.00 SMA2014.89% SMA5016.47% SMA20067.67% Volume6,308,171 Change2.76%
May-04-21 09:15AM  
Apr-29-21 09:37AM  
Apr-22-21 04:30PM  
Apr-19-21 08:53AM  
Mar-23-21 09:00AM  
Mar-04-21 10:11AM  
Feb-19-21 04:47PM  
Feb-17-21 12:28AM  
Feb-16-21 09:15AM  
Feb-08-21 08:35AM  
Feb-04-21 10:16AM  
Feb-02-21 08:00AM  
Jan-28-21 08:35AM  
Jan-27-21 01:00PM  
Jan-25-21 07:00AM  
Jan-06-21 09:00AM  
Dec-18-20 12:57AM  
Dec-15-20 09:40AM  
Dec-09-20 09:40AM  
Dec-08-20 09:15AM  
Dec-03-20 03:30PM  
Nov-30-20 09:15AM  
Nov-10-20 09:30AM  
Nov-09-20 09:30AM  
Oct-27-20 09:00AM  
Oct-13-20 07:30AM  
Oct-07-20 07:00AM  
Sep-30-20 09:45AM  
Sep-29-20 10:17AM  
Sep-22-20 08:15AM  
Sep-15-20 10:17AM  
Sep-08-20 10:00AM  
Sep-01-20 04:34PM  
Aug-27-20 09:00AM  
Aug-26-20 10:00AM  
Aug-13-20 09:45AM  
Aug-10-20 03:18PM  
Aug-05-20 05:32PM  
Aug-04-20 08:17AM  
Jul-22-20 10:30AM  
Jul-20-20 02:00PM  
Jul-14-20 08:47AM  
Jul-13-20 08:15AM  
Jun-30-20 08:54AM  
Jun-29-20 09:07AM  
Jun-26-20 09:00AM  
Jun-23-20 08:49AM  
Jun-22-20 01:17PM  
Jun-02-20 09:30AM  
May-26-20 08:15AM  
May-18-20 02:30PM  
May-15-20 06:49AM  
May-14-20 09:00AM  
May-13-20 08:15AM  
May-12-20 08:00AM  
Apr-27-20 09:30AM  
Apr-01-20 08:07AM  
Mar-26-20 09:06AM  
Mar-18-20 09:46AM  
Mar-16-20 06:22AM  
Mar-03-20 04:45PM  
Feb-26-20 08:00AM  
Feb-25-20 08:00AM  
Feb-10-20 08:28AM  
Feb-04-20 08:00AM  
Feb-03-20 08:00AM  
Jan-27-20 08:00AM  
Dec-19-19 08:00AM  
Dec-04-19 08:00AM  
Nov-08-19 08:00AM  
Oct-24-19 08:00AM  
Oct-15-19 08:00AM  
Oct-07-19 08:30AM  
Oct-03-19 07:00AM  
Sep-28-19 07:52AM  
Sep-27-19 11:28AM  
Sep-25-19 07:00AM  
Sep-04-19 06:55AM  
Aug-29-19 08:00AM  
Jul-30-19 08:00AM  
Jul-24-19 03:38PM  
May-24-19 08:53AM  
May-13-19 08:47AM  
May-01-19 08:00AM  
Apr-30-19 09:45AM  
Apr-23-19 08:30AM  
Apr-05-19 07:15PM  
Apr-04-19 08:30AM  
Apr-01-19 09:00AM  
Mar-12-19 08:45AM  
Mar-11-19 02:23PM  
Feb-27-19 12:30PM  
Jan-25-19 08:00AM  
Jan-08-19 09:00AM  
Jan-04-19 10:45AM  
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.